CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME

Clinical trial NCT07449923 · RECRUITING

Trial details

NCT number: NCT07449923
Sponsor: EyePoint Pharmaceuticals, Inc.
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Diabetic Macular Edema DME Diabetic Macular Edema (DME)

Start date: 2026-02-09
Primary completion: 2027-10-01
Enrollment: 240

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.